FDA briefing documents: Sofosbuvir safe, effective

Share this article:

Gilead's sofosbuvir hep. C drug is safe and effective when used in combination with other therapies. That pronouncement, reported by Reuters today, is not likely to shock anyone, although FDA briefing documents posted on the agency's site ahead of an advisory panel meeting Friday may offer some hints at what reviewers will focus on.

As the news service notes, Gilead is seeking approval to market the drug, sans interferon (INF) but with existing treatment ribavirin (RBV), for patients with the genotype 2 and genotype 3 variants of the diasease. Gilead will also seek approval for use of the drug, with RBV and INF, for patients with the more common genotype 1 variant, as well as for 4, 5 and 6.

Sofosbuvir is vying to become the basis for the first approved all-oral drug for hep. C. Analysts have modeled peak worldwide sales of between $4 billion and $7 billion a year. All-oral regimens are also being tested by BMS and AbbVie.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.